News

VivaWell and Shen.AI Announce Strategic Partnership to Transform Health Monitoring in Mexico and Argentina

MEXICO CITY, MEXICO / ACCESSWIRE / May 20, 2024 / In a significant move to revolutionize digital health and wellness…

2 years ago

Hypha Labs Announces New Patent Filing

New Patent Portfolio Unveiled Revolutionizing Psilocybin ProcessingLAS VEGAS, NV / ACCESSWIRE / May 20, 2024 / Hypha Labs, Inc. (OTC…

2 years ago

CNS Pharmaceuticals to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase

Live webcast fireside chat on Tuesday, May 21st at 1:40 PM ETHOUSTON, TX / ACCESSWIRE / May 20, 2024 /…

2 years ago

Nava Health To Attend 4th Annual Benchmark Virtual Healthcare Conference

COLUMBIA, MD / ACCESSWIRE / May 20, 2024 / Nava Health MD, Inc. ("Nava Health" or "Nava"), a leader in…

2 years ago

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others SHELTON, CT / ACCESSWIRE / May 20,…

2 years ago

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T…

2 years ago

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided…

2 years ago

Nanox to Report First Quarter and Financial Results on May 28, 2024

PETACH TIKVA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative…

2 years ago

LIXTE Biotechnology Holdings Provides Update on Recent Activities

Publishing of Findings in Recent Pre-Clinical Study for LIXTE’s Proprietary Compound, LB-100, in New Field of Cancer Biology, “Activation Lethality”Presentation…

2 years ago